The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3803-3811

  Perik, Patrick J ^a   De Vries, Elisabeth G E ^a   Boomsma, Frans ^b   Messerschmidt, Juergen ^c   Van Veldhuisen, Dirk J ^a   Sleijfer, Dirk T ^a   Gietema, Jourik A ^a   Van Der Graaf, Winette T A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

Author keywords

Anthracyclines; Apoptotic cytokines; Breast cancer; Cardiotoxicity; High dose chemotherapy

Indexed keywords

C REACTIVE PROTEIN; CARBOPLATIN; EPIRUBICIN; FAS ANTIGEN; FAS LIGAND; TAMOXIFEN; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL ARTICLE; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOOD PROTEINS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HEART; HUMANS; TAMOXIFEN;

EID: 33750738224     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, De Vries EG and Sleijfer DT: Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 26: 429-447, 2000.
2. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M and Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717, 1979.
3. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE and Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808-815, 1991.
4. Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, De Vries EG, Sleijfer DT and Van der Graaf WT: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19: 2746-2753, 2001.
5. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R and Fosser V: Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 35: 323-334, 2005.
6. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW and Khaw BA: Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182-1189, 1996.
7. Perik PJ, De Vries EG, Gietema JA, van der Graaf WT, Sleijfer DT, Suurmeijer AJ and van Veldhuisen DJ: The dilemma of the strive for apoptosis in oncology: mind the heart. Crit Rev Oncol Hematol 53: 101-113, 2005.
8. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB and Mann DL: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93: 704-711, 1996.
9. Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, Yasuda N, Sano H, Kumada H, Takemura M, Noma A, Tanaka T, Watanabe S and Fujiwara H: Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 29: 1214-1220, 1997.
10. Yndestad A, Kristian DJ, Geir EH, Holm T, Haug T, Simonsen S, Froland SS, Gullestad L and Aukrust P: Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 54: 175-182, 2002.
11. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Young MS and Lin SJ: Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 147: 931-938, 2004.
12. Perik, PJ, Van der Graaf WT, De Vries EG, Boomsma F, Messerschmidt J, Van Veldhuisen DJ, Sleijfer DT and Gietema JA: Circulating apoptosis-related proteins in long-term disease-free breast cancer survivors. Acta Oncol 47: 175-183, 2006.
13. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM and De Vries EG: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349: 7-16, 2003.
14. Gelevert T, Messerschmidt J, Meinardi MT, Alt F, Gietema JA, Franke JP, Sleijfer DT and Uges DR: Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin. Ther Drug Monit 23: 169-173, 2001.
15. Von Hoff DD, Rozencweig M, Layard M, Slavik M and Muggia FM: Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62: 200-208, 1977.
16. Sheen-Chen SM, Chen WJ, Eng HL and Chou FF: Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 43: 211-215, 1997.
17. Jablonska E: Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment. Cytokine 10: 540-543, 1998.
18. Ueno T, Toi M and Tominaga T: Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 5: 3529-3533, 1999.
19. Sheen-Chen SM, Chen HS, Eng HL and Chen WJ: Circulating soluble Fas in patients with breast cancer. World J Surg 27: 10-13, 2003.
20. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Yamamoto T, Horie H, Sugimoto Y and Kinoshita M: Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 37: 2086-2092, 2001.
21. Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, Kempf W, Schubert A, Schuler G and Hambrecht R: Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 42: 861-868, 2003.
22. Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F, Biasucci LM and Maseri A: Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation 103: 2236-2241, 2001.
23. Cascino I, Fiucci G, Papoff G and Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154: 2706-2713, 1995.
24. Aderka D, Engelmann H, Maor Y, Brakebusch C and Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175: 323-329, 1992.
25. Miura M, Friedlander RM and Yuan J: Tumor necrosis factor-induced apoptosis is mediated by a CrmA-sensitive cell death pathway. Proc Natl Acad Sci USA 92: 8318-8322, 1995.
26. Tanaka M, Suda T, Takahashi T and Nagata S: Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 14: 1129-1135, 1995.
27. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 277: 12687-12690, 1996.
28. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR and Sleijfer DT: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355: 1075-1076, 2000.
29. de Vos FYFL, Nuver J, Willemse PHB, van der Zee AGJ, Messerschmidt J, Burgerhof JGM, de Vries EGE and Gietema JA: Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage. Eur J Cancer 40: 696-700, 2004.
30. Katsura K, Nomura S, Ohtani T, Matsumoto N, Shimizu T, Yamaguchi K, Kishimoto Y, Kitajima H and Fukuhara S: Changes of immunological markers after autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 124: 633-640, 1998.
31. Lub-De Hooge MN, De Jong S, Vermot-Desroches C, Tulleken JE, De Vries EGE and Zijlstra JG: Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. Shock 22: 186-188, 2004.
32. Marsik C, Halama T, Cardona F, Wlassits W, Mayr F, Pleiner J and Jilma B: Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock 20: 493-496, 2003.
33. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL and Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89: 4845-4849, 1992.
34. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermüller J and Wilmanns W: Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75: 1011-1016, 1990.
35. Or R, Kalinkovich A, Nagler A, Weisman Z, Naparstek E, Weiss L and Hahn T: Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications. Cytokines Mol Ther 2: 243-250, 1996.